Intravascular antithrombotic magnetic control device

Abstract

The utility model relates to an intravascular antithrombotic magnetic control device which comprises an intravascular device and an external magnetic control device, the intravascular device comprises a medicine carrying assembly, a conveying catheter and a release control module, and the medicine carrying assembly and the release control module are respectively arranged in the conveying catheter; the external magnetic control device is used for fixing one end of the conveying catheter and is in communication connection with the release control module. The utility model has the benefits that the structure is simple, the design is reasonable, the release of suppository particles is accurately controlled through an external magnetic field, the minimally invasive treatment of a patient is realized, and safety and reliability are realized.

Description

TECHNICAL FIELD

[0001] The utility model relates to the technical field of anti-thrombus, specifically relates to a kind of intravascular anti-thrombus magnetic control device. BACKGROUND

[0002] Thrombosis is a common complication during and after vascular surgery, especially in veins and arteries, thrombus can cause serious consequences, such as pulmonary embolism, deep vein thrombosis, heart attack and stroke. The existing anti-thrombus treatment method mainly depends on drug treatment and mechanical device, but these technologies have the following shortcomings:

[0003] (1) Drug therapy limitations: systemic drug administration (such as intravenous injection) often requires a large dose to achieve therapeutic effect, which can easily cause systemic side effects, such as bleeding risk and drug resistance; Poor targeting, unable to accurately control the release of antithrombotics in the local area.

[0004] (2) Limitations of mechanical devices: current intravascular devices (such as catheters or stents) can only passively deliver antithrombotics, and cannot achieve real-time control and accurate targeted therapy; There is a risk of foreign body reaction and device displacement during use.

[0005] (3) Inadequate intraoperative control: when using anti-thrombus technology during surgery, the release amount of antithrombotics cannot be controlled in real time, making it difficult to respond to the dynamic changes of thrombosis.

[0006] In summary, the existing technology cannot achieve safe, efficient and accurate anti-thrombus treatment during and after surgery. UTILITY MODEL CONTENT

[0007] The utility model provides a kind of intravascular anti-thrombus magnetic control device, to solve the problems in prior art.

[0008] The technical solution of the utility model to solve the above technical problems is as follows:

[0009] An intravascular anti-thrombus magnetic control device includes an intravascular device and an external magnetic control device. The intravascular device includes a drug-loaded component, a delivery catheter and a release control module. The drug-loaded component and the release control module are placed in the delivery catheter. The external magnetic control device is used to fix one end of the delivery catheter and is communicatively connected to the release control module.

[0010] The utility model has the beneficial effects that during use, the intravascular device is sent to the target site in the patient's blood vessel by the delivery catheter, and the external magnetic control device is used for fixation. Then, the external magnetic control device controls the drug-loaded component to release microparticles by using the release control module, so that the drug has a concentrated effect in the target area, achieving good therapeutic effect.

[0011] The utility model discloses simple structure, reasonable in design, through the accurate control of the release of the counteracting suppository particle of external magnetic field, realize the minimally invasive treatment of patient, safe and reliable.

[0012] On the basis of the above technical scheme, the utility model still can make following improvement.

[0013] Further, the external magnetic control device includes an electromagnetic coil and an energy supply module, and the energy supply module is in communication connection with the electromagnetic coil and the release control module respectively.

[0014] The beneficial effect of the above further scheme is simple structure, reasonable in design, and the electromagnetic coil generates a controllable magnetic field to adjust the particle release rate; at the same time, the energy supply module provides energy for the intravascular device through wireless energy supply technology.

[0015] Further, the drug-loaded assembly includes a magnetic member and an antithrombotic agent coating layer, and the magnetic member and the antithrombotic agent coating layer are respectively arranged in the delivery catheter.

[0016] The beneficial effect of the above further scheme is simple structure, reasonable in design, and the release of particles in the antithrombotic agent coating layer is controlled through the magnetic field to ensure the treatment effect.

[0017] Further, the external magnetic control device further includes a control terminal, and the control terminal is in communication connection with the energy supply module.

[0018] The beneficial effect of the above further scheme is simple structure, reasonable in design, and the control terminal controls the operation of each component, and the control terminal can display the distribution of intravascular particles in real time and dynamically adjust the magnetic field parameters.

[0019] Further, the control terminal is a tablet computer.

[0020] The beneficial effect of the above further scheme is simple structure, and it is reasonable to use a tablet computer as the control terminal, which is convenient to use.

[0021] Further, the release control module is built-in with a micro sensor, the micro sensor is in communication connection with the external magnetic control device, and is used for monitoring pressure and flow rate changes.

[0022] The beneficial effect of the above further scheme is simple structure, reasonable in design, and the micro sensor is used for monitoring pressure and flow rate changes.

[0023] Further, the delivery catheter is a flexible pipe.

[0024] The beneficial effect of the above further scheme is simple structure, and it is reasonable to use a flexible pipe as the delivery catheter, which can ensure the treatment effect and the comfort of the patient during the treatment process.

[0025] Further, the delivery catheter is a polyurethane catheter.

[0026] The beneficial effect of the above further scheme is simple structure, and the polyurethane catheter is reasonable for the delivery catheter, has certain hardness, and is convenient to operate.

[0027] Further, the delivery catheter is a silica gel tube.

[0028] The beneficial effect of the above further scheme is simple structure, and the silica gel tube is reasonable for the delivery catheter, has certain hardness, and is convenient to operate.

[0029] Further, the outer wall of the delivery catheter is coated with an anti-adhesion coating.

[0030] The beneficial effect of the above further scheme is simple structure, and the anti-adhesion coating is reasonable for the outer wall of the delivery catheter, so that blood protein adhesion is reduced. BRIEF DESCRIPTION OF DRAWINGS

[0031] Figure 1 It is a structural schematic view of the utility model.

[0032] In the drawings, the component list represented by each sign is as follows:

[0033] 1, delivery catheter; 2, release control module; 3, electromagnetic coil; 4, energy supply module; 5, magnetic piece; 6, anti-thrombotic agent coating layer; 7, control terminal; 8, micro sensor. DETAILED DESCRIPTION

[0034] It should be noted that the embodiments in the utility model and the features in the embodiments can be combined with each other without conflict.

[0035] In the description of the utility model, it should be understood that the orientation or position relationship indicated by the terms "center", "longitudinal", "lateral", "upper", "lower", "front", "rear", "left", "right", "vertical", "horizontal", "top", "bottom", "inner", "outer" and the like is the orientation or position relationship shown in the drawings, and is only for the convenience of describing the utility model and simplifying the description, and cannot be understood as indicating or implying that the indicated device or element must have a particular orientation, be constructed and operated in a particular orientation, and therefore cannot be understood as a limitation on the utility model. In addition, the terms "first", "second" and the like are only for the purpose of description, and cannot be understood as indicating or implying relative importance or implicitly indicating the number of the indicated technical features. Therefore, the features limited by "first", "second" and the like can explicitly or implicitly include one or more features. In the description of the utility model, unless otherwise specified, the meaning of "multiple" is two or more.

[0036] In the description of the utility model, it needs to explain, unless another explicit stipulation and limitation, the term " install " " link " " connection " should do broad sense understanding, for example, can be fixed connection, also can be detachable connection, or integrally connected, can be mechanical connection, also can be electrical connection, can be direct connection, also can through the intermediate medium indirectly connect, can be two element inside the intercommunication. For ordinary skilled person in the art, the above-mentioned term can be understood by the specific meaning in the utility model through specific circumstances.

[0037] The utility model will be described in detail below with reference to the drawings and in combination with embodiments.

[0038] Embodiment 1

[0039] As Figure 1 Indicated, the utility model provides a kind of intravascular antithrombotic magnetic control device, including intravascular equipment and external magnetic control equipment, the intravascular equipment includes drug-loading component, delivery catheter 1 and release control module 2, the drug-loading component and the release control module 2 are placed in the delivery catheter 1 respectively;The external magnetic control equipment is used to fix one end of the delivery catheter 1, and is connected with the release control module 2 communication.

[0040] In use, the intravascular equipment is sent to the target site in the patient's blood vessel using the delivery catheter 1, and is fixed using the external magnetic control equipment;Then, the external magnetic control equipment controls the drug-loading component to release microparticles using the release control module 2, so that the drug concentrates in the target area to achieve good therapeutic effect.

[0041] It should be noted that the above-mentioned release control module 2 uses prior art, which will not be described here.

[0042] The embodiment has simple structure and reasonable design, and precisely controls the release of antithrombotic particles by external magnetic field, realizes minimally invasive treatment of patients, and is safe and reliable.

[0043] Embodiment 2

[0044] On the basis of embodiment 1, in the embodiment, the external magnetic control equipment includes electromagnetic coil 3 and energy supply module 4, and the energy supply module 4 is connected with the electromagnetic coil 3 and the release control module 2 in communication.

[0045] The scheme has simple structure and reasonable design, and the electromagnetic coil 3 generates controllable magnetic field to adjust the release rate of microparticles, and the energy supply module 4 provides energy for the intravascular device by wireless energy supply technology.

[0046] It should be noted that the above-mentioned electromagnetic coil 3 and energy supply module 4 respectively use prior art, which will not be described here.

[0047] Embodiment 3

[0048] In the embodiment, the drug-loaded assembly comprises the magnetic member 5 and the anti-thrombotic coating 6, which are respectively arranged in the delivery conduit 1.

[0049] The scheme has simple structure and reasonable design, and the release of the particles in the anti-thrombotic coating 6 is controlled by the magnetic field, thereby ensuring the treatment effect.

[0050] Preferably, in the embodiment, the magnetic member 5 and the anti-thrombotic coating 6 are arranged in the delivery conduit 1 close to the other end thereof.

[0051] It should be noted that the magnetic member 5 and the anti-thrombotic coating 6 are both prior art, which will not be described herein.

[0052] Embodiment 4

[0053] In the embodiment, the external magnetic control device further comprises a control terminal 7, which is in communication connection with the energy supply module 4.

[0054] The scheme has simple structure and reasonable design, and the operation of each component is controlled by the control terminal 7, which can display the distribution of the particles in the blood vessel in real time and dynamically adjust the magnetic field parameters.

[0055] Embodiment 5

[0056] In the embodiment, the control terminal 7 is a tablet computer.

[0057] The scheme has simple structure, and it is reasonable and convenient to use the tablet computer as the control terminal 7.

[0058] Embodiment 6

[0059] In the embodiment, the release control module 2 is internally provided with a micro sensor 8, which is in communication connection with the external magnetic control device and is used for monitoring the changes in pressure and flow rate.

[0060] The scheme has simple structure and reasonable design, and the changes in pressure and flow rate are monitored by the micro sensor.

[0061] It should be noted that the micro sensor 8 is prior art, which will not be described herein.

[0062] Embodiment 7

[0063] In the embodiment, the delivery conduit 1 is a flexible tube.

[0064] The scheme has simple structure, and the flexible pipe is reasonable for the conveying conduit 1, which can ensure treatment effect and comfort of the patient in the treatment process.

[0065] Embodiment 8

[0066] In the embodiment, the conveying conduit 1 is a polyurethane conduit on the basis of the embodiment 7.

[0067] The scheme has simple structure, and the polyurethane conduit is reasonable for the conveying conduit 1, which has certain hardness and is convenient to operate.

[0068] Embodiment 9

[0069] In the embodiment, the conveying conduit 1 is a silica gel pipe on the basis of the embodiment 7.

[0070] The scheme has simple structure, and the silica gel pipe is reasonable for the conveying conduit 1, which has certain hardness and is convenient to operate.

[0071] The embodiment 8 and the embodiment 9 are parallel schemes.

[0072] Embodiment 10

[0073] In the embodiment, the outer wall of the conveying conduit 1 is coated with an anti-adhesion coating on the basis of the above embodiments.

[0074] The scheme has simple structure, and it is reasonable to coat the outer wall of the conveying conduit 1 with the anti-adhesion coating, so that the blood protein adhesion is reduced.

[0075] Preferably, the anti-adhesion coating is preferably a phosphatidylcholine coating in the embodiment.

[0076] The working principle of the utility model is as follows:

[0077] In the use process, the intravascular device is sent to the target position in the blood vessel of the patient by the conveying conduit 1, and is fixed by the external magnetic control device; then, the external magnetic control device controls the drug-loaded assembly to release the microparticles by the release control module 2, so that the drug is concentrated in the target area, so that good treatment effect is achieved.

[0078] The intravascular anti-thrombotic magnetic control device has the following advantages:

[0079] 1, precision: through the external magnetic control technology, the local precise release of the anti-thrombotic agent is realized, and the systemic side effects are significantly reduced.

[0080] 2, real-time: dynamically control the release rate, which can timely respond to the complex situation of thrombus formation in the operation.

[0081] 3. Targeted: Anti-thrombotic microparticles concentrate in the target vascular region, improving treatment efficiency.

[0082] 4. Minimally invasive and safe: Flexible catheter and biocompatible material design reduce vascular operation trauma and foreign body reactions.

[0083] 5. Convenient postoperative maintenance: External magnetic control device supports recovery and energy replenishment of unreleased microparticles, reducing long-term implantation risks.

[0084] 6. Wide applicability: The device is suitable for various vascular surgery scenarios, such as venous thrombectomy, arterial stent implantation, valve replacement, etc.

[0085] 7. Cost control: Simple device structure and low material cost have broad market promotion potential.

[0086] It should be noted that all electronic components involved in the present application are based on existing technology, and the above-mentioned components are electrically connected, and the control circuit between each component is based on existing technology.

[0087] For those skilled in the art, it is obvious that the present application is not limited to the details of the above exemplary embodiments, and can be realized in other specific forms without departing from the spirit or essential characteristics of the present application. Therefore, from any point of view, the embodiments should be considered as exemplary and non-limiting, the scope of the present application is defined by the appended claims rather than the above description, and therefore all changes falling within the meaning and scope of the equivalent elements of the claims are intended to be included in the present application. Any reference signs in the claims should not be considered as limiting the claims involved.

[0088] In addition, it should be understood that although the present application is described in the form of an embodiment, not every embodiment contains only one independent technical solution, and the description of the specification is only for clarity, those skilled in the art should consider the specification as a whole, and the technical solutions in each embodiment can be appropriately combined to form other embodiments that those skilled in the art can understand.

[0089] The above is only the preferred embodiment of the present application, and is not intended to limit the present application, and any modification, equivalent replacement, improvement, etc. made within the spirit and principles of the present application shall be included in the protection scope of the present application.

Claims

1. An intravascular antithrombotic magnetic control device, characterized in that: The device includes an intravascular device and an external magnetic control device. The intravascular device includes a drug-carrying component, a delivery catheter (1), and a release control module (2). The drug-carrying component and the release control module (2) are respectively placed inside the delivery catheter (1). The external magnetic control device is used to fix one end of the delivery catheter (1) and is communicatively connected to the release control module (2).

2. The intravascular antithrombotic magnetic control device according to claim 1, characterized in that: The external magnetic control device includes an electromagnetic coil (3) and an energy supply module (4), and the energy supply module (4) is communicatively connected to the electromagnetic coil (3) and the release control module (2).

3. The intravascular antithrombotic magnetic control device according to claim 2, characterized in that: The drug delivery assembly includes a magnetic component (5) and an antithrombotic agent coating layer (6), which are respectively placed inside the delivery conduit (1).

4. The intravascular antithrombotic magnetic control device according to claim 2, characterized in that: The external magnetic control device also includes a control terminal (7), which is communicatively connected to the energy supply module (4).

5. The intravascular antithrombotic magnetic control device according to claim 4, characterized in that: The control terminal (7) is a tablet computer.

6. The intravascular antithrombotic magnetic control device according to any one of claims 1-5, characterized in that: The release control module (2) has a built-in micro sensor (8), which is connected to the external magnetic control device for monitoring pressure and flow rate changes.

7. The intravascular antithrombotic magnetic control device according to any one of claims 1-5, characterized in that: The delivery conduit (1) is a flexible tube.

8. The intravascular antithrombotic magnetic control device according to claim 7, characterized in that: The delivery conduit (1) is a polyurethane conduit.

9. The intravascular antithrombotic magnetic control device according to claim 7, characterized in that: The delivery conduit (1) is a silicone tube.

10. The intravascular antithrombotic magnetic control device according to any one of claims 1-5, characterized in that: The outer wall of the delivery conduit (1) is coated with an anti-adhesion coating.

Images